Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Danavorexton - Takeda

Drug Profile

Danavorexton - Takeda

Alternative Names: TAK-925

Latest Information Update: 26 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Class Cyclohexanes; Esters; Ethers; Piperidines; Sleep disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action Orexin receptor type 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neurological disorders; Sleep apnoea syndrome
  • Phase I Narcolepsy; Respiration disorders
  • No development reported Idiopathic hypersomnia

Most Recent Events

  • 01 Feb 2024 Phase-II clinical trials in Neurological disorders (IV) (Takeda pipeline; February 2024)
  • 31 Jul 2023 Danavorexton is still in phase-I trials for Narcolepsy (In adults, In the elderly) in Japan(IV, Injection) (Takeda pipeline; July 2023)
  • 28 Jun 2023 No recent reports of development identified for phase-I development in Idiopathic-hypersomnia(In the elderly, In adults) in Japan (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top